instructions): The mlsslon of the Pllot and Feasibility Program at the UCSD/UCLA DRC is to foster the development of new invesfigators and provide seed support for high-risk diabetes-related research projects with an emphasis on translational science. The core is directed by Dr. Pinchas Cohen, who is also DRC Associate Director, and a member of the Nafional Diabetes Centers Directors Executive Committee. Over the last decade, the program funded 41 scienfists (28 over the last 5 years, facilitated by an ARRA supplement to the DRC for the support of P&F projects), over 90% of which have been young investigators and more that 95% of them are still active in diabetes research. These investigators garnered an impressive post-funding record of addifional NIH support and published a large amount of papers in high impact journals. These achievements underscore the exceptional pipeline of young investigators that exists in our insfitufions. Specific Objecfives for the P&F Program in this compefifive renewal applicafion are to confinue to: ?promote emerging diabetes projects and future scientific leaders;advertise, inform and engage the diabetes research communifies regarding the DRC P&F and its opportunifies;facilitate and speed transition to external funding;leverage institutional matching support, infrastructure, and technologies towards the success of P&F projects;synergize with other institutional training and research programs;create access for emerging diabetes researchers to the latest research technologies and state-of-the-art facilities and services; foster collaborative research among junior and senior scientists;promote leadership skills;and implement oversight and programmatic review of the P&F program and its awardees. We propose to fund five $50,000 grants each year to provide support for collecfing preliminary data sufficient to support ROI grant applicafions with a focus on newer invesfigators and translafional research. We have established a process of advertising, solicifing, reviewing, awarding, and (if necessary) terminafing P&F projects. This program is assisted by mulfiple experienced external reviewers. We leveraged substanfial institufional matching support from all of the institutions that comprise the DRC, to support promising proposals. Using this institutional matching support, each year, we will fund a sixth, $50,000 P&F award;and one grant per year will be identified as a """"""""junior faculty developmental award"""""""" and will receive an addifional $25,000 in year one and will also receive institufional support of $50,000 for a second year. Finally, we will support P&F awards with $10,000 of credit towards use in DRC cores. .

Public Health Relevance

Given the Strong leadership ofthe UCSD/UCLA P&F Program;the innovative ancillary programs available to the awardees, and the emphasis on supporting young investigators that have a remarkable record of success, we expect this program to enable us to substantially advance our goal of continuing our strong track record of producing independent investigators performing cutting-edge translational diabetes research. This will promote the continued advancement of diabetes care and research regionally and nationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK063491-11
Application #
8443942
Study Section
Special Emphasis Panel (ZDK1-GRB-S (O2))
Project Start
Project End
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
11
Fiscal Year
2013
Total Cost
$365,413
Indirect Cost
$129,663
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Cardamone, Maria Dafne; Tanasa, Bogdan; Cederquist, Carly T et al. (2018) Mitochondrial Retrograde Signaling in Mammals Is Mediated by the Transcriptional Cofactor GPS2 via Direct Mitochondria-to-Nucleus Translocation. Mol Cell 69:757-772.e7
Pappas, D J; Lizee, A; Paunic, V et al. (2018) Significant variation between SNP-based HLA imputations in diverse populations: the last mile is the hardest. Pharmacogenomics J 18:367-376
Muse, Evan D; Yu, Shan; Edillor, Chantle R et al. (2018) Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proc Natl Acad Sci U S A 115:E4680-E4689
Floyd, J S; Sitlani, C M; Avery, C L et al. (2018) Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J 18:127-135
Mahajan, Anubha (see original citation for additional authors) (2018) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet 50:559-571
Hajek, Catherine; Guo, Xiuqing; Yao, Jie et al. (2018) Coronary Heart Disease Genetic Risk Score Predicts Cardiovascular Disease Risk in Men, Not Women. Circ Genom Precis Med 11:e002324
Malik, Rainer (see original citation for additional authors) (2018) Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 50:524-537
Kulminski, Alexander M; Huang, Jian; Loika, Yury et al. (2018) Strong impact of natural-selection-free heterogeneity in genetics of age-related phenotypes. Aging (Albany NY) 10:492-514
Gao, Chuan; Tabb, Keri L; Dimitrov, Latchezar M et al. (2018) Exome Sequencing Identifies Genetic Variants Associated with Circulating Lipid Levels in Mexican Americans: The Insulin Resistance Atherosclerosis Family Study (IRASFS). Sci Rep 8:5603
Seyerle, A A; Sitlani, C M; Noordam, R et al. (2018) Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. Pharmacogenomics J 18:215-226

Showing the most recent 10 out of 926 publications